The effect of metabolic syndrome on psychological characteristics and quality of life in patients with arterial hypertension

The combined course of arterial hypertension (AH) and metabolic syndrome (MS) leads to an increased risk of cardiovascular complications, type 2 diabetes mellitus and overall mortality. Psychological factors play an important role in the emergence and development of hypertension and MS. Affective mental disorders and psychosocial stress can aggravate the course of this pathology, reducing the quality of life of patients. Purpose of the study. To study the effect of MS on the mental state and quality of life in patients with hypertension based on the results of psychodiagnostic testing. Materials and methods. 120 outpatients were examined. The 1st group (comparison) included 63 patients with AH, the 2nd (main) group included 57 patients with AH and MS. The following scales were used: psychosocial stress scale of L. Rieder et al., Hospital Anxiety and Depression Scale (HADS), Abbreviated Multifactor Personality Questionnaire (SMOL), Quality of Life Scale (SF-36). Results. The frequency of psychosocial stress in AH with MS was 93%, and in AH it was 67% (p < 0.001). High stress was 2 times more common in AH patients with MS than in AH patients. Anxiety disorders were detected in 72%, and depressive disorders in 79% of AH patients with MS, which is much more common than in AH patients. Quality of life indicators on a number of scales of physical and mental components of health were lower in AH with MS than in AH. Conclusion. The data obtained indicate a significant deterioration in mental health and quality of life in patients with hypertension on the background of MS.

1. Williams B., Mancia G., Spiering W., Agabiti Rosei E., Azizi M., Burnier M., Clement D.L., Coca A. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019;40(5):475. DOI: 10.1093/eurheartj/ehy686.

2. Padwal R.S., Bienek A., McAlister F.A., Campbell N.R.; Outcomes Research Task Force of the Canadian Hypertension Education Program. Epidemiology of Hypertension in Canada: An Update. Can J Cardiol. 2016;32(5):687-694. DOI: 10.1016/j.cjca.2015.07.734.

3. Ibrahim M.S., Pang D., Randhawa G., Pappas Y. Risk models and scores for metabolic syndrome: systematic review protocol. BMJ Open. 2019;9(9):e027326. DOI: 10.1136/bmjopen-2018-027326.

4. Gubergrits N.B., Belyaeva N.V., Klochkov A.E. Metabolic syndrome: how to avoid polypharmacy? Moscow: Prima Print. 2017; 96 p. (in Russ.)

5. Mills K.T., Bundy J.D., Kelly T.N., Reed J.E., Kearney P.M., Reynolds K., Chen J., He J. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016;134(6):441-450. DOI: 10.1161/CIRCULATIONAHA.115.018912.

6. Rosenbaum S., Stubbs B., Ward P.B., Steel Z., Lederman O., Vancampfort D. The prevalence and risk of metabolic syndrome and its components among people with posttraumatic stress disorder: a systematic review and meta-analysis. Metabolism. 2015;64(8):926-933. DOI: 10.1016/j.metabol.2015.04.009.

7. Zhang J., Liu N., Yang C. Effects of rosuvastatin in combination with nimodipine in patients with mild cognitive impairment caused by cerebral small vessel disease. Panminerva Med. 2019;61(4):439-443. DOI: 10.23736/S0031-0808.18.03475-4.

8. Mendelevich B.D., Burykin I.M., Khafizyanova R.Kh. Rationale for including mental health assessment in primary health care. The Russian journal of preventive medicine. 2021;24(2):14-19 (in Russ.). DOI: 10.17116/profmed20212402114. EDN: FVBNMO

9. Agarkov N.M., Ohotnikov O.I., Korneeva S.I., Moskaleva E.O., Moscalev A.A., Colomyec V.I., Markelova A.M., Markelova E.A. Psychological continuum of elderly patients suffering from arterial hypertension with metabolic syndrome, against the background of chronotherapy with a fixed combination of amlodipine, lisinopril and rosuvastatin.Russian Journal of Cardiology. 2021;26(2):90-96 (in Russ.). DOI: 10.15829/1560-4071-2021-4312. EDN: DYYDAV.

10. Chazova I.E. Clinical guidelines. Metabolic syndrome. 2013. 43 p. (in Russ.). URL: https: //mzdrav.rk.gov.ru/file/mzdrav _18042014_

11. Garvey W.T., Garber A.J., Mechanick J.I., Bray G.A., Dagogo-Jack S., Einhorn D., Grunberger G., Handelsman Y. et al. American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. Endocr Pract. 2014;20(9):977-989. DOI: 10.4158/EP14280.PS.

12. Chazova I.E., Zhernakova Yu.V. Diagnosis and treatment of arterial hypertension [guidelines]. Systemic hypertension. 2019;16(1):6-31 (in Russ.). DOI: 10.26442/2075082X.2019.1.190179. EDN: AEZOAN.

13. Zaitsev V.P., Ayvazyan Т.А. Application for the psychological test SMOL of an objective assessment of the level of psychological adaptation of patients with chronic somatic diseases. Current issues of restorative medicine. 2005. (in Russ.)

14. Chukaeva I.I., Plotnikova N.A., Ahmatova F.D., Rumiancev A.G., Spiridonova E.A. Prolonged stress effect on daily variability of blood pressure indicators in women. Medical Alphabet. 2017;34(2):18-21 (in Russ.). EDN: ZVGRFZ.

15. Shemerovsky K.A., Firova M.E., Shabrov A.V. Levels of anxiety and depression in patients with metabolic syndrome. Medical Academic Journal. 2013(S):83-84 (in Russ.)

16. Fominykh Yu.A., Gorbacheva I.A., Uspensky Yu.P., Gulunov Z.X, Sousova Ya.V. Psychological status and quality of life of patients with metabolic syndrome. Medical alphabet. 2019;20(3):46-50 (in Russ.). DOI: 10.33667/2078-5631-2019-2-20(395)-46-50. EDN: OTZQLF.

17. Mendelevich B.D., Burykin I.M., Hafizyanova R.H. Justification of the inclusion of mental health assessment in the stage of primary health care. The Russian journal of preventive medicine. 2021;24(2):14-19 (in Russ.). DOI: 10.17116/profmed20212402114. EDN: FVBNMO.

18. Drapkina O.M., Ivanova A.A. The possibilities of personalized medicine in the fight against chronic non-communicable diseases: achievements and prospects. Kardiologiya. 2021;61(11):98-103 (in Russ.). DOI: 10.18087/cardio.2021.11.n1233. EDN: BTFTTI.